Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: A case-control study

Lancet

Volumn 353, Issue 9171, 1999, Pages 2190-2194

  Rzany, Berthold ^a   Correia, Osvaldo ^b   Kelly, Judith P ^c   Naldi, Luigi ^d   Auquier, Ariane ^e   Stern, Robert ^f  

^a MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^c BOSTON UNIVERSITY   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DRUG USE; FEMALE; FRANCE; GERMANY; HUMAN; INFANT; ITALY; MAJOR CLINICAL STUDY; MALE; NEWBORN; PORTUGAL; PRIORITY JOURNAL; RISK ASSESSMENT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 0033606436     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)05418-X     Document Type: Article

References (29)

1. Tennis P., Stern R. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology. 49:1997;542-546.
2. Roujeau J.C., Kelly J.P., Naldi L.et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 333:1995;1600-1607.
3. Bastuji S., Rzany B., Stern R.S., Shear N.H., Naldi L., Roujeau J.C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol. 125:1993;92-96.
4. Stern R.S., Chan H.L. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol. 121:1989;317-322.
5. Leenutaphong V., Sivayathorn A., Suthipinittharm P., Sunthonpalin P. Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol. 32:1993;428-431.
6. Roujeau J.C., Guillaume J.C., Fabre J.P., Penso D., Flechet M.L., Girre J.P. Toxic epidermal necrolysis (Lyell's syndrome): incidence and drug etiology in France, 1981-1985. Arch Dermatol. 126:1990;37-42.
7. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2 and 3: study of sixty cases. J Am Acad Dermatol. 13:1985;623-635.
8. Schöpf E., Stühmer A., Rzany B., Victor N., Zentgraf R., Kapp J.F. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol. 127:1991;839-842.
9. Chan J.L., Stern R.S., Arndt K.A.et al. The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 126:1990;43-47.
10. Rzany B., Mockenhaupt M., Baur S.et al. Epidemiology of erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Germany (1990-1992): structure and results of a population based registry. J Clin Epidemiol. 49:1996;769-773.
11. Kelly J.P., Auquier A., Rzany B.et al. An international collaborative case-control study of severe cutaneous adverse reactions (SCAR): design and methods. J Clin Epidemiol. 48:1995;1099-1108.
12. Goodman LS, Gilman AG. The pharmacological basis of therapeutics, 7th edn. New York: Macmillan, 1985: 446-472.
13. Miettinen O.S. Estimability and estimation in case-referent studies. Am J Epidemiol. 109:1976;226-235.
14. Chaffin J.J., Davis S.M. Suspected lamotrigine-induced toxic epidermal necrolysis. Ann Pharmacother. 31:1997;720-723.
15. Duval X., Chosidow O., Semah F., Lipsker D., Frances C., Herson S. Lamotrigine versus carbamazepine in epilepsy. Lancet. 345:1995;1301-1302.
16. Fogh K., Mai J. Toxic epidermal necrolysis after treatment with lamotrigine. Seizure. 6:1997;63-65.
17. Sachs B., Ronnau A.C., Ruzicha T., Gleichmann E., Schuppe H.C. Lamotrigine and toxic epidermal necrolysis. Lancet. 348:1996;1597.
18. Sullivan J.R., Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous ciclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol. 37:1996;208-212.
19. Wadelius M., Karlson T., Wadelius C., Rane A. Lamotrigine and toxic epidermal necrolysis. Lancet. 348:1996;1041.
20. Sterker M., Berrouschot J., Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Pharmacol Ther. 33:1995;595-597.
21. Borg M.F., Brobert J.C., Zwi L.J. Is phenytoin contraindicated in patients receiving cranial irradiation? Australas Radiol. 39:1995;42-46.
22. Delattre J.Y., Safai B., Posner J.B. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology. 38:1988;194-198.
23. Maiche A., Teerenhovi L. Stevens-Johnson syndrome in patients receiving radiation therapy. Lancet. ii:1985;145.
24. Nawalkha P.L., Mathur N.K., Malhotra Y.K., Saksena H.C. Severe erythema multiforme (Stevens-Johnson syndrome) following telecobalt therapy. Br J Radiol. 45:1972;768-769.
25. Inachi S., Mizutani H., Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol. 133:1997;845-849.
26. Paul C., Wolkenstein P., Adle H.et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 134:1996;710-714.
27. Chen M., Quintas J., Fuks Z., Thompson C., Kufe D.W., Weichselbaum R. Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor alpha and ceramide. Cancer Res. 55:1995;991-994.
28. Dewey W.C., Ling C.C., Meyn R.E. Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys. 33:1995;781-796.
29. Asmark H., Wiholm B. Epidemiology of adverse reactions to carbamazepine as seen in spontaneous reporting systems. Acta Neurol Scand. 81:1990;131-140.